Related Experiment Video
Updated: Jun 27, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Considerations for the antiretroviral management of women in 2008
1Louisiana State University Health Science Center, HIV Outpatient Program, 136 S. Roman St, New Orleans, LA 70112, USA. rclark@lsuhsc.edu
Abstract:
Clinicians should be familiar with sex-specific considerations when managing antiretroviral (ARV) treatment among women. Pregnancy is a critical influence on when to start treatment and what ARVs should be included in a regimen. Sex, pregnancy and hormonal contraceptive therapies can each influence ARV pharmacokinetic profiles. Women may be prone to have higher serum levels with selected ARV treatments, which may improve potency but also increase the risk for toxicities. Several studies have demonstrated that women do have higher frequencies of selected ARV-associated adverse events when compared with men. Although HIV treatment guidelines for nonpregnant women do not differ from men, clinicians should be aware of the high potential for certain ARV-related toxicities and follow suggestions in order to decrease the risk of side effects.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Retroviruses
Therapeutic Drug Monitoring: Affecting Factors
Inhibitors of Viral Protein Synthesis
Pharmacokinetics in Pediatric Patients: Drug Excretion

